

### **OPEN ACCESS**

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

\*CORRESPONDENCE
Christiane Ghakis
Christiane.Ghakis@msd.com

RECEIVED 24 September 2025 ACCEPTED 30 September 2025 PUBLISHED 14 October 2025

#### CITATION

Gill J, House AA, Chagla Z, Tchervenkov J, Kim SJ, Vinson A, Cervera C, Keown PA, Sun SLW, Khoury C and Ghakis C (2025) Correction: Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada. *Front. Immunol.* 16:1712602. doi: 10.3389/fimmu.2025.1712602

### COPYRIGHT

© 2025 Gill, House, Chagla, Tchervenkov, Kim, Vinson, Cervera, Keown, Sun, Khoury and Ghakis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Correction: Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada

John Gill<sup>1</sup>, Andrew A. House<sup>2</sup>, Zain Chagla<sup>3</sup>, Jean Tchervenkov<sup>4</sup>, S. Joseph Kim<sup>5</sup>, Amanda Vinson<sup>6</sup>, Carlos Cervera<sup>7</sup>, Paul A. Keown<sup>1</sup>, Sonia Lai Wing Sun<sup>8</sup>, Christina Khoury<sup>8</sup> and Christiane Ghakis<sup>8</sup>\*

<sup>1</sup>Department of Medicine, University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Department of Medicine, Western University, London, ON, Canada, <sup>3</sup>Department of Medicine, McMaster University, Hamilton, ON, Canada, <sup>4</sup>Department of Surgery, McGill University, Montreal, QC, Canada, <sup>5</sup>Department of Medicine, University of Toronto, Toronto, ON, Canada, <sup>6</sup>Department of Medicine, Dalhousie University, Halifax, NS, Canada, <sup>7</sup>Department of Medicine, University of Alberta, Edmonton, AB, Canada, <sup>6</sup>Medicial Affairs, Merck Canada Inc. Kirkland, QC, Canada

KEYWORDS

cytomegalovirus, kidney transplantation, antiviral prophylaxis and treatment, immunosuppression, superinfection, leukopenia, hospitalization, graft failure

## A Correction on

Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada

By Gill J, House AA, Chagla Z, Tchervenkov J, Kim SJ, Vinson A, Cervera C, Keown PA, Sun SLW, Khoury C and Ghakis C (2025). Front. Immunol. 16:1618748. doi: 10.3389/fimmu.2025.1618748

There was a mistake in Figure 2 as published. The X axis legend was incorrect and should read: "Days from transplant to onset of the 1st episode of myelotoxicity". The corrected Figure 2 appears below.

The original version of this article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Gill et al. 10.3389/fimmu.2025.1712602

